ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
PR Newswire•04/11/2026•09:00 ET
0
Key Highlights
- ➤LOTIS-7 combination: 88.7% ORR and 75.3% CRR among 97 patients
- ➤MZL Phase 2 monotherapy: 93% ORR and 74.4% CRR among 43 patients
- ➤LOTIS-5: median PFS improved to 6.14 months versus 4.73 months with R-GemOx
- ➤LOTIS-5: no statistically significant overall-survival difference between treatment arms
- ➤FDA raised serious concerns about LOTIS-5 results at a recent pre-sBLA meeting
Expert Statements
Mohamed Zaki, Chief Medical Officer of ADC Therapeutics
“We are pleased by the breadth of the ZYNLONTA clinical program and the growing body of evidence showcased through multiple presentations at ASH. We are particularly encouraged by the strength of the updated LOTIS-7 data and the marginal zone lymphoma IIT data, which are both highly differentiated and continue to show deep and durable efficacy with manageable safety.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“We believe the emerging data from LOTIS-7 and MZL reinforce the best-in-class potential of ZYNLONTA in these settings and support our pursuit of an expanded role in treating these B-cell malignancies through potential compendia and regulatory pathways. ASH provides an important opportunity to engage with the hematology community on these findings and discuss plans to advance the clinical program, including planned Phase 3 studies. Through ZYNLONTA, we remain focused on delivering meaningful outcomes for patients in need while driving long-term value for our shareholders.”
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program PR Newswire
ZYNLONTA data to be featured across 5 oral presentations and multiple posters
Get started
Create a free account to read the full story.